Terveystalo Oyj (HEL:TTALO)
Finland flag Finland · Delayed Price · Currency is EUR
7.60
+0.02 (0.26%)
Apr 28, 2026, 6:29 PM EET
← View all transcripts

Earnings Call: Q1 2025

Apr 25, 2025

Kati Kaksonen
VP, Investor Relations & Sustainability, Terveystalo

Good morning, everybody, and welcome to Terveystalo's Q1 results webcast and conference call. My name is Kati Kaksonen. I'm responsible for Terveystalo Investor Relations and Sustainability. As usual, our CEO, Ville Iho, and our CFO, Juuso Pajunen, will present the results and will follow that with a Q&A. We'll take questions from the phone lines as well as through the webcast and from the audience if there are any. Without further ado, over to you, Ville.

Ville Iho
President and CEO, Terveystalo

Thank you, Kati. Diving into Q1 very shortly through the key numbers. All in all, solid start of the year and continuing on the improvement path that we have laid out during the last two years. Marching it up, our adjusted EBIT is up by 20%, EPS up by 40%, against slightly dropping revenue line, which is then again due to softness in Sweden, softness in portfolios, and some discontinued outsourcing contracts in portfolios.

Healthcare Services are still growing with healthy 5%, but all in all, a flat quarter in revenue. Very glad to still see our NPS, customer satisfaction, trending upwards as it has done throughout the improvement journey that we have conducted. A strong, solid start for this year 2025. Looking at different businesses, if there's one headline for the agenda, it's improvement.

As we have communicated previously, we are looking for still incremental improvement in Healthcare Services, which is already on a very strong place. Q1 was one step in that journey. In portfolio businesses in Sweden, we are looking for more drastic performance improvement against tough market conditions in portfolios and in Sweden.

I'm very glad to say that both of these businesses have been able to improve their relative profitability. First step in Sweden to see the real benefits of our turnaround agenda and turnaround program in our bottom line numbers. Portfolios continue to do good work against fairly tough market conditions and incrementally improving their performance. The agenda is solid. Improvement will be there across the board.

Taking a slightly longer view on our strategic agenda and strategic KPIs, it's been again a solid improvement in efficiency, organic growth, but also in underlying forward-looking KPIs like NPS, customer satisfaction, and people engagement index, where we also see all-time high figures and a positive trend going forward.

Also, medical quality measured with the pay index trending nicely to positive territory and at all-time high. All in all, we have not only been able to improve the financial performance step by step, but also underlying forward-looking KPIs in our strategic agenda. With that one, I will hand over to Juuso.

Juuso Pajunen
CFO, Terveystalo

Thank you, Ville. Good morning all. Happy to be here and proud to present our numbers for Q1. I'm Juuso Pajunen, the CFO of Terveystalo Group. If we start on the group level, I have to say solid performance at group level. Some might say even strong performance. We have been doing quite well. If we look on the totals and we start from bottom up, our EPS went up 41% like Ville told.

Our adjusted EBIT is almost 20% up and our EBITA is 14% up. We have a throughout solid performance from the income statement KPIs. What is more important if we look on the picture is that all of our business segments improved in their relative profitability. We are getting the demand in.

We have the improved operational efficiency and we have a favorable service mix, especially in the healthcare services that yields now into our results. If we look on the top line, we have healthcare services having a healthy almost 5% demand against one working day less compared to the previous quarter. We have the portfolio businesses where especially outsourcing contracts contributed to negative revenue development.

We have Sweden where we are working on our turnaround program and progressing as planned. If we go a bit deeper into each segment and start with the healthcare services, healthcare services continues to be the revenue driver and the profit driver in our group. If we look into the supply and the booking rates, they are on a good level. What is good to understand on the demand is that the flu season continued to be strong.

We had some 25,000-30,000 visits more contributing on the stronger flu season now compared to the previous year. That helped our both the service mix and also having an impact on the customer mix, which on a big scale are fairly normal, but we see that in the total demand. If we then think about further our profitability and our revenues were supported by our service sales and channel mix and then the pricing.

To improve our transparency towards markets, we have now updated how we show this one to you in the future. If we take a view on the growth and the revenue bridge, as said, almost 5% up. Our visits are moderately growing with somewhat 0.4 percentage points if we adjust for the working days. The rest of the growth is coming from the service sales and channel mix in total.

All in all, a robust result in Healthcare Services supported by organic growth and an efficient operation model. If we then go to see the portfolio businesses, we have seen that the publicly funded market remains cautious. We see this one especially in the staffing where part of the decline in the revenues is still coming from our selection of customer contracts. We have the outsourcing where we are EUR 10 million down.

We have earlier told that we will this year lose revenues in the ballpark of EUR 25 million. It will be first half heavy and that estimate of EUR 25 million has not changed despite this EUR 10 million at the moment. If we look on the consumer-driven markets, we see dental is going up despite the headwind from the one working day less. We are almost 5% up.

Also, massage services, we see that the demand is picking up. However, it is good to note that these are coming against quite weak comparables when it comes to demand. All in all, what is important is that we are improving our adjusted EBIT percentage. We are now going back on the improvement both on EBITA level and EBIT level in total in the portfolios.

Our agenda is working, but we have some stickiness in the public sector market at the moment that creates headwinds in the revenue. If we go to Sweden, we have difficult market conditions. The Swedish economy has not been recovering and has been impacted by the global turmoil to a certain extent. That has made our market environment difficult. At the same time, we have been able to improve our efficiency.

Our [Uncertain] is having a clear impact and it will continue to have the impact. We are within our plan. We would obviously benefit from support from the markets, but our improvement plan does not require that one. We are getting forward in here. We are improving our relative profitability and we will continue to do so. If we look into our investments, our balance sheet and our investment levels are fairly normal.

We have a slight pickup to EUR 42 million in the latest 12 months period. As we have since CMD and already earlier communicated, we will prioritize organic growth investments and disciplined in-organic expansion. Disciplined M&A is part of our plan. Very focused organic growth driving investments are what we will continue to do.

This 42 million will modestly ramp up in the coming quarters also towards the vicinity of 4% on the revenues or slightly above that one in the longer term. If we then look on the cash flow, we have EUR 202 million of operating cash flow on the last 12 months. It is a solid good performance, but it needs to be put into context that in 2024 we made more profits that comes with taxes that were paid out now.

We have a tax impact in here. If we look at the Q4 numbers or then Q1 2024 numbers, it's good to note that the Q4 LTM has two strong quarters within that one. This is normal volatility within the cash flow that we are seeing. The profits that we are making convert in a very high ratio into cash.

If we look on the balance sheet, we are net debt to EBITDA at 2.2. If we would take against adjusted EBITDA, we would be at 2. Our balance sheet is strong and we have all the power needed to invest in our growth in the future. Finally, let's talk about guidance for 2025. First, it is unchanged. We are saying that the full year revenues are going to grow and our adjusted EBIT will be between 10.7%-11.8% of the revenue, while previous year was 10.5%.

The estimates are based on stable demand environment, employment levels, and typical morbidity rates. We have the EUR 25 million reduction what comes to the outsourcing contract. We reiterate what we have said. At the same time, having said that one, we all know that there is some global uncertainty and turmoil in the world.

There are the tariffs from Trump and there are different types of forces in play at the moment. We are not immune to those ones. There are scenarios where they could have indirect impact to us. We do not export to the U.S. The tariffs do not mean anything to us in that sense. What we buy will not be impacted by that one either.

The indirect impact, if Finnish employment levels would be starting to go down, if the employment levels in Sweden would start to go down, those could have an impact on our operations. We deem it fairly unlikely based on the mega trends on our services and based on the need and the value that we provide to clients that it would have a material impact. We are very comfortable to reiterate our guidance for this year.

If you look now, our performance in Q1, the solid improvement what comes to previous year performance, it is fair to say that if you take all the scenarios that are at the moment meaningful to us, it is the scenarios that are above the midpoint of the guidance are probably more likely to occur than those ones that are below the guidance. Obviously, it is up to you to put your own scenarios into place, but that is how it looks like to us.

We are within the range, but potentially the upper part of the range is more likely at the moment. With these ones, I'm happy to reiterate our guidance for 2025. We are going to grow and our adjusted EBIT margin will be between 10.7% and 11.8%. With these ones, let's invite Kati on board and start the Q&A.

Kati Kaksonen
VP, Investor Relations & Sustainability, Terveystalo

Thanks, Juuso. Do we have any questions from the phone lines?

Operator

If you wish to ask a question, please dial #5 on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial #6 on your telephone keypad. The next question comes from Sami Sarkamies from Danske Bank. Please go ahead.

Sami Sarkamies
Senior Equity Analyst, Danske Bank

Hi, I have several questions. We'll take this one by one. First, starting from the guidance, you didn't narrow the guidance range even though Q1, as I said, is a strong quarter, should de-risk the outlook. Can you talk about the reservations? You mentioned tariffs and indirect impact, but are there other things that make you worried?

Juuso Pajunen
CFO, Terveystalo

I do not think we are worried. I think that our guidance is robust and it is at the moment relevant. We all do need to acknowledge that there are also forces in play that are more unpredictable than maybe a year or two years ago what comes to the whole macroeconomic environment.

At the same time, what could happen? As said, the employment levels are a topic that could have a midterm impact to our operations. As said, I think that it is more likely that we are on the upper end of the range. I could imagine scenarios also below the midpoint, but those ones seem to be a bit less likely at the moment than the other scenarios.

Sami Sarkamies
Senior Equity Analyst, Danske Bank

Okay, thanks. I would like to check a couple of things regarding portfolio businesses. Firstly, if we think about the outsourcing business, was it so that you're not expecting any further contract expiries after Q1? This is sort of the level you will be having throughout the year.

Juuso Pajunen
CFO, Terveystalo

Yes, from our we have been quite consistently and continuously showing the graph at the appendix of the presentations, and EUR 25 million is the expectation of lost volume for this year. It is always an approximation, but that's the ballpark number. It is correct. There are minor impacts, pluses and minuses coming from, for example, pass-through items within such contracts, but that's still our best understanding of the situation.

Sami Sarkamies
Senior Equity Analyst, Danske Bank

Okay, and what about then staffing? Are you sort of satisfied with the profitability of the current staffing business, and is that something you want to retain throughout the year?

Juuso Pajunen
CFO, Terveystalo

If you look, the staffing market has been difficult, and that is not then Terveystalo staffing market. It is the total healthcare staffing market as we see it, and as we have proxies on that one. That is the main driver what comes to staffing. On top of that, we have made some conscious choices on not to retain certain agreements during last year, which are now visible on the revenue line.

What comes to profitability, our staffing is a good business. It is making benchmark profits for our purposes. We are happy with that one, and the operating model is fairly resilient on changes on the revenue levels. We have no further need to discuss on that topic. It is a good business, but with unfortunate market conditions.

Sami Sarkamies
Senior Equity Analyst, Danske Bank

Okay, and then finally, dental and massage services, it seems that you finally turned the corner on those in Q1. Are you expecting sort of positive growth figures from now on?

Juuso Pajunen
CFO, Terveystalo

From our current perspective, our guidance says that we are expecting improvement in all segments, so that one obviously refers to profitability and portfolios. The current trend suggests that now there's a turnaround on consumer-driven demand what comes to these services. It is still good to note that the comparable are from fairly weak demand point of time. We are expecting this to continue improving.

Sami Sarkamies
Senior Equity Analyst, Danske Bank

Yeah. Okay, and then finally on the cash flow, a bit slow start for the year. I think you mentioned taxes as one of the reasons. Any sort of timing impacts? If we think about the full year cash flow outlook, how does it look relative to last year?

Juuso Pajunen
CFO, Terveystalo

Yeah, I th ink that in total, our cash conversion, the longer timespan you take, our cash conversion is very, very stable. I think that that will continue in the future. I have no reason to believe that it would not continue. As I already said in the Q4 quarterly release, we had an exceptionally good Q4. For the full year 2024, we had also a good Q1.

There are always timing differences when you close balance sheet on 31st of March. That creates a bit of volatility. Now we had negative volatility earlier. We have had positive volatility, and we have been fairly open about that one. I do not think there is anything drastic or more to say on that one other than that we are a cash machine and we continue to be a cash machine.

Sami Sarkamies
Senior Equity Analyst, Danske Bank

Okay, thanks. I don't have any further questions.

Operator

There are no more questions at this time, so I hand the conference back to the speakers.

Kati Kaksonen
VP, Investor Relations & Sustainability, Terveystalo

All right, we have some questions from the webcast audience, maybe starting from the global macro environment and the tariffs that the Trump administration has imposed. Do they have any impact on the business going forward?

Juuso Pajunen
CFO, Terveystalo

Yeah, if I reiterate what I said on Sami's first question, it is difficult to see direct impacts hitting us. It is easy to understand that indirect impacts may occur. Basically, we do not export, we do not import. We buy only for our own services, for our own needs.

Direct impacts are not there. Indirectly, if Finnish economy goes into bad shape, if Swedish economy goes into bad shape, and it impacts both the employment and the consumer demand, obviously we are not in a void. We have protection on the services we provide, on the need for our services that makes us less volatile, but we are living in the same economy as everyone else.

Kati Kaksonen
VP, Investor Relations & Sustainability, Terveystalo

Anything that you want to add, Ville?

Ville Iho
President and CEO, Terveystalo

Maybe taking one step back and looking at the longer trends. One is to remember, first of all, that, as Juuso referred to, we have been a very resilient business against different cycles. That continues to be the case. We are not in a bubble, but more resilient than the rest of the guys, at least most of the guys. Looking at the mega trends, regardless of the cycle, mega trends continue to support a longer-term increase in demand for healthcare services, and we are well positioned in that play.

Kati Kaksonen
VP, Investor Relations & Sustainability, Terveystalo

Absolutely. Referring to the strategic agenda, of course, we are continuously working on the value created for our customers and the efficiency of the services to also be able to maneuver around the changes in the landscape better. Maybe then going into the portfolio businesses and the public sector, there is a question if our exposure to the public sector contracts is becoming a liability considering the uncertainty and the budget cuts in the welfare regions.

Ville Iho
President and CEO, Terveystalo

There was a time or a place in time when our then-existing portfolio was a bit of a liability. That was due to the fact that it was not hedged against inflation that the world had not seen for a couple of decades. That was the only reason. Now, the agreement portfolio that we have in place is solid.

It is robust, it is profitable, and it is adequately hedged to different conditions and creating positive cash flow. We are looking positively on the public market, even though it has been fairly silent. Now we have the first large contracts being tendered coming into the latter part of this year, which is interesting and a sign that the public market will start to open up.

Juuso Pajunen
CFO, Terveystalo

Maybe just to remind everyone that public sector businesses are fairly proportionately small when it comes to our total revenues. We are primarily a private money business. I would even say that some of these wellbeing county cuts will give an opportunity for the private sector to demonstrate how efficient we are. Let's see how the games and plays fold out as we go forward.

Kati Kaksonen
VP, Investor Relations & Sustainability, Terveystalo

Absolutely. A couple of questions on the top line. First, on the Healthcare Services specifically, could you open up a bit, Juuso, whether the 6.1% growth in the services and sales mix/pricing in the Healthcare Services is more driven by price rather than the mix changes, and how should one think about those?

Juuso Pajunen
CFO, Terveystalo

I think that first of all, we have not opened up that one, and it is a fairly complex equation to even open up. You need to remember that we have in our mix, we have a channel mix. Whether it goes to remote or physical, we have a service mix.

Whether it's appointments, whether it's diagnostics, whether it's surgery. We have a customer mix, whether it is a corporate customer, consumer customer, public sector customer, or insurance customer. The mix impact is a fairly important part of this equation. Also, in that 6%, it is a fairly important part because now we need to remember that the other part of our pricing has some kind of a link to inflation.

We have been in our CMDs and other financial events, we have been stating that we can, due to our service mix and due to our value to customers, we can be slightly above the inflation, also due to scarcity of resources when it comes to healthcare professionals. You can look a bit on the inflation, and then you can think a bit on top of that one, and then you have the mix impact, which seems to be higher than the inflation impact, if we put it like that. As said, this is a fairly complex equation.

Kati Kaksonen
VP, Investor Relations & Sustainability, Terveystalo

Maybe then talking about the guidance on the top line. In the Q1, the sales went down by approximately 1% year on year, yet we are still guiding for growth for this year. How confident are we that the sales will actually grow rather than remain flat this year?

Juuso Pajunen
CFO, Terveystalo

Yeah, at the moment, I can reiterate our guidance. We are expecting that we are growing this year. Obviously, there are the same disclaimers and variations as within the guidance in total, but that is our current best guess.

Kati Kaksonen
VP, Investor Relations & Sustainability, Terveystalo

Yeah, and of course, our main focus continues to be on the EBIT margin.

Juuso Pajunen
CFO, Terveystalo

Absolutely correct. We are in for EPS enhancement as per our financial targets, and that one we have been very successful.

Kati Kaksonen
VP, Investor Relations & Sustainability, Terveystalo

Great. Going back into the Healthcare Services, once again, we had a record-level quarter when it comes to the EBIT margin. How much of room for improvement do we still see in this area going forward?

Ville Iho
President and CEO, Terveystalo

It is a market which is a good place to be and a position which is a good place to be for Terveystalo. We have a good agenda in place for organic growth and efficiency both, and there is additional potential to improve the performance. The internal agenda, for example, for the efficiency will take us quite far from where we are today.

I am really confident that we can improve efficiency and performance based on that one. The rest is related to market conditions. We are not in a vacuum, and I am sure the rest of the guys and at least the green competitor will improve as well. We are not in a bubble, but internally there is a lot to do. We have great potential, great agenda in place.

Kati Kaksonen
VP, Investor Relations & Sustainability, Terveystalo

Absolutely. Anything that you want to add there, Juuso?

Juuso Pajunen
CFO, Terveystalo

No, I think Ville said it all.

Kati Kaksonen
VP, Investor Relations & Sustainability, Terveystalo

Great. At the moment, we don't have any other questions from the webcast. Do we have any questions in the audience?

Roni Peuranheimo
Equity Analyst, Inderes

Roni Peuranheimo from Inderes, hi. Maybe a couple of questions regarding the portfolio business, maybe about the staffing. The market seems to be hard at the moment. Do you see any permanent changes in the staffing market in Finland, or is it a transitionary market?

Ville Iho
President and CEO, Terveystalo

If I start, it is a good question. Maybe one needs to look at how it then evolved over the last couple of years. From the outset, it is a fairly low-barrier entry business model, at least when you look at the business from outside. Post-COVID and during COVID, there was an influx of new entrants into that market, driven mainly by bottlenecks in the public sector and bottlenecks in the nursing services.

That in a way encouraged new supply to come into the market, which a lot of the supply was healthy. Now what we are seeing is that since the market has been turning, it is saturating, the long tail of the new supply is starting to drop out.

I would say it is a cycle, but when there is a cycle, there typically happens some permanent changes. We trust in our model. We have been here for, let's say, 20 years. We can be more agile in directing our supply wherever the need is. We have an excellent supply of professionals, and we have sources where to source them. As Juuso said, it is a good business. There has been a difficult cycle, but we trust in that one.

Juuso Pajunen
CFO, Terveystalo

It is good to note that there are the synergies. This is a supply-driven environment. What is not in the staffing is supply somewhere else. It has an important part in our business.

Roni Peuranheimo
Equity Analyst, Inderes

All right, thank you. Maybe one more about the dental business where you have big ambitions. Maybe if you could talk about how your synergies with healthcare services have developed here recently.

Juuso Pajunen
CFO, Terveystalo

Yes, if I start and Ville can complement. I think that we are seeing progress what comes to synergies in healthcare services. We have different types of synergy potential in here. We have the occupational health clientele, which is clearly a place where more and more clients would like to include dental into their healthcare plans. We have the consumer market synergies, especially brand-driven. We have the back-end synergies, which are more coming from the network.

As you know and see from our Healthcare Services results and capability to run that network, obviously dental benefits also from that one. All in all, we are seeing progress in that end. I would also say that we have quite a journey to walk also, that we have lots of room to improve.

Ville Iho
President and CEO, Terveystalo

Nothing to add.

Roni Peuranheimo
Equity Analyst, Inderes

All right, no further questions. Thank you.

Kati Kaksonen
VP, Investor Relations & Sustainability, Terveystalo

Great. I do not think that we have any further questions in the audience either. Thank you, everybody, for joining us today, and have a great weekend once that arrives.

Ville Iho
President and CEO, Terveystalo

Thank you.

Juuso Pajunen
CFO, Terveystalo

Thank you.

Powered by